SMA, a myogenic marker often present in a broad range of soft tissue cancers, including smooth muscle tumors, fibroblastic/myofibroblastic sarcomas, and angiomyolipomas, may be detectable in SFTs, but to a lesser degree [24]. The gene discussed is SMN1; the disease is angiomyolipoma.